Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

Dusunen Adam. 2015; 28(2): 140-146


Antipsychotic-like effect of agomelatine in a rodent model

Oytun Erbas, Betul Elikucuk, Volkan Solmaz, Huseyin Serdar Akseki, Murat Semiz.




Abstract

Objective: Agomelatine is a naphthalene bioisostere of melatonin. Melatonin is involved in several neurophysiological systems; nevertheless, data about the relationship between melatonin and psychosis such as schizophrenia are limited and contradictory. In this study, we examined the antipsychotic-like effects of agomelatine in a rodent model.
Method: In this study, we evaluated the effect of agomelatine on novelty-induced rearing behavior and apomorphine-induced stereotypical behavior in male rats. Agomelatine (20 and 40mg/kg, i.p.), chlorpromazine (1mg/kg, i.p.), or isotonic NaCl (1mL/kg, i.p.) were administered to four groups of rats (n=6), respectively. An hour later, apomorphine (2mg/kg, s.c.) was administered to each rat.
Results: Our results showed that either dose of agomelatine decreased rearing behavior in rats significantly, in a dose dependent manner. Agomelatine also decreased the stereotypical behaviour scores like chlorpromazine did.
Conclusion: We conclude that agomelatine has beneficial effects on rearing and stereotypical behaviour, which were accepted to be indicators of antipsychotic effect.

Key words: Agomelatine, apomorphine, psychosis






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.